Medical Radiology and Radiation Safety. 2023. Vol. 68. № 6

DOI:10.33266/1024-6177-2023-68-6-86-91

O.V. Gribova, Zh.A. Startseva, E.L. Choynzonov, V.A. Novikov, A.I. Ryabova,
V.I. Shtin

Combined Treatment of Salivary Gland Cancer Patients with the Use of High-Let Radiation

Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia

Contact person: O.V. Gribova, e-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

ABSTRACT

The purpose: To evaluate the efficiency of combined treatment of patients with salivary gland cancer using neutron therapy. 

Material and methods: The study included 130 patients with salivary gland cancer who underwent combined treatment with adjuvant neutron or standard photon radiotherapy. Neutron therapy was performed on a cyclotron U-120. The average energy of fast neutrons was 6.3 MeV. 

Results: There was observed a significant decrease in the frequency of relapses in the group of patients who received a postoperative course of NT compared with the control group (21.1 % vs. 45 %, p<0.05). The five-year overall survival in the study group was 73.8±9.5 %, in the control group ‒ 43.2±9.4% (p<0.05). The value of five-year relapse-free survival in the study group was 65.6±7.5 %, in the control group ‒ 34.8±9.1 % (p<0.05). Erythema of the skin in the irradiation area (grade I) was the most frequent type of local acute radiation reaction and was observed in 60 % of patients in the study group and in 25 % of patients in the control group. The most frequent late complication in both groups of patients was skin atrophy and subcutaneous fibrosis (grade I on the RTOG/EORTC scale). In the study group, this indicator was 34.4 %, in the control group ‒ 20 % (p>0.05). 

Conclusion: Thus, the study confirmed the high effectiveness of fast neutron therapy against malignant tumors of the salivary glands. Neutron therapy does not cause serious complications, encourages to increase of patients life expectancy and to decrease the number of relapses after combined treatment in comparison with standard methods of treatment.

Keywords: salivary gland cancer, neutron therapy, combined treatment, fast neutrons

For citation: Gribova OV, Startseva ZhA, Choynzonov EL, Novikov VA, Ryabova AI, Shtin VI. Combined Treatment of Salivary Gland Cancer Patients with the Use of High-Let Radiation. Medical Radiology and Radiation Safety. 2023;68(6):86–91. (In Russian). DOI:10.33266/1024-6177-2023-68-6-86-91

References

1. El-Naggar A.K. Tumours of Salivary Glands. WHO Classification of Head and Neck Tumours. Ed. El-Naggar A.K., JKC C., Grandis J.R., Takata T., Slootweg P.J. Lyon, France, WHO Press, 2017. P. 159–202.

2. Catterall M., Errington R.D. The Implications of Improved Treatment of Malignant Salivary Gland Tumors by Fast Neutron Radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1987;13:1313-1318. https://doi.org/10.1016/0360-3016(87)90222-7 10.1016/0360-3016(87)90222-7.

3. Goodhead D.T. Neutrons Are Forever! Historical Perspectives. Int. J. Radiat. Biol. 2019;95;7:957-984. doi: 10.1080/09553002.2019.1569782.

4. Mardynskiy Yu.S., Sysoyev A.S., Gulidov I.A. Technological Problems of Using of Fast Neutron Research Reactors for Radiation Therapy in Patients with Malignant Tumors. Vestnik Rentgenologii I Radiologii = Journal of Radiology and Nuclear Medicine. 1997;4:26-29 (In Russ.).

5. Kandakova E.Yu., Vazhenin A.V., Kuznetsova A.I., Vazhenin I.A., Panshin G.A., Tsallanova Z.S. Results of the Combined Photon-Neutron Therapy in the Conditions of Escalation of a Dose of Neutrons Generally a Course of the Combined Photon-Neutron Therapy. Vestnik Rossiyskogo Nauchnogo Tsentra Rentgenoradiologii MZ Rossii. 2014;14-4:7 (In Russ.).

6. Velikaya V.V., Startseva Zh.A., Goldberg V.E., Popova N.O., Lisin V.A. Long-Term Treatment Outcomes after Neutron Therapy for Patients with Locally Recurrent Breast Cancer. Onkologicheskiy Zhurnal: Luchevaya Diagnostika, Luchevaya Terapiya = Journal of Oncology: Diagnostic Radiology and Radiotherap. 2019;2;1:27-32 (In Russ.). https://doi.org/10.37174/2587-7593-2019-2-1-27-32.

7. Choynzonov E.L., Lisin V.A., Gribova O.V., Novikov V.A., Startseva Zh.A. Neytronnaya Terapiya Zlokachestvennykh Novoobrazovaniy Golovy i Shei = Neutron Therapy of Head and Neck Cancer. Moscow Publ., 2021 P. 328 (In Russ.). 

8. Von der Grün J., Winkelmann R., Rödel F., Balster S., Neumayer T., Ghanaati S., et al. Patterns of Care, Toxicity and Outcome in the Treatment of Salivary Gland Carcinomas: Long-Term Experience from a Tertiary Cancer Center. Eur. Arch. Otorhinolaryngol. 2021;278;11:4411-4421. doi:10.1007/s00405-021-06652-5.

9. Freitag V., Lettmaier S., Semrau S., Hecht M., Mantsopoulos K., Müller S.K., et al. High-Grade Salivary Gland Cancer: Is Surgery Followed by Radiotherapy an Adequate Treatment to Reach Tumor Control? Results from a Tertiary Referral Centre Focussing on Incidence and Management of Distant Metastases. Eur. Arch. Otorhinolaryngol. 2022;279;5:2553-2563. doi: 10.1007/s00405-021-07024-9. 

10. Mahmood U., Koshy M., Goloubeva O., Suntharalingam M. Adjuvant Radiation Therapy for High-Grade and/or Locally Advanced Major Salivary Gland Tumors. Arch. Otolaryngol Head Neck. Surgery. 2011;137:1025–1030. doi: 10.1001/archoto.2011.158.

11. Terhaard C.H.J., Lubsen H., Van der Tweel I., Hilgers F.J.M., Eijkenboom W.M.H., Marres H.A.M., et al. Salivary Gland Carcinoma: Independent Prognostic Factors for Locoregional Control, Distant Metastases, and Overall Survival: Results of the Dutch Head and Neck Oncology Cooperative Group. Head Neck. 2004;26:681–693. doi: 10.1002/hed.10400. 

12. Safdieh J., Givi B., Osborn V., Lederman A., Schwartz D., Schreiber D. Impact of Adjuvant Radiotherapy for Malignant Salivary Gland Tumors. Otolaryngol Head Neck Surg. 2017;157:988-994. https://doi.org/10.1177/0194599817717661 10.1177/0194599817717661.

13. Lee A., Givi B., Osborn V.W., Schwartz D., Schreiber D. Patterns of Care and Survival of Adjuvant Radiation for Major Salivary Adenoid Cystic Carcinoma. Laryngoscope. 2017;127:2057-2062. https://doi.org/10.1002/lary.26516 10.1002/lary.26516.

14. Jang J.Y., Choi N., Ko Y.H., Chung M.K., Son Y.I., Baek C.H., et al. Treatment Outcomes in Metastatic and Localized High-Grade Salivary Gland Cancer: High Chance of Cure with Surgery and Post-Operative Radiation in T1-2 N0 High-Grade Salivary Gland Cancer. BMC Cancer. 2018;18;1:672. doi: 10.1186/s12885-018-4578-0.

15. Cheraghlou S., Kuo P., Mehra S., Agogo G.O., Bhatia A., Husain Z.A., et al. Adjuvant Therapy in Major Salivary Gland Cancers: Analysis of 8580 Patients in the National Cancer Database. Head Neck. 2018;40;7:1343-1355. doi: 10.1002/hed.24984. 

16. Meyers M., Granger B., Herman P., Janot F., Garrel R., Fakhry N., et al. Head and Neck Adenoid Cystic Carcinoma: a Prospective Multicenter Refcor Study of 95 Cases. Eur. Ann. Otorhinolaryngol Head Neck Dis. 2016;133;1:13-17. doi: 10.1016/j.anorl.2015.09.009.

17. Kokemueller H., Eckardt A., Brachvogel P., Hausamen J.E. Adenoid Cystic Carcinoma of the Head and Neck--a 20 Years Experience. Int. J. Oral. Maxillofac Surg. 2004;33;1:25-31. doi: 10.1054/ijom.2003.0448. 

18. Lindsley K.L., Cho P., Stelzer K.J., et al. Clinical Trials of Neutron Radiotherapy in the United States. Bull. Cancer Radiother. 1996;83Suppl:78s-86s. https://doi.org/10.1016/0924-4212(96)84889-4 10.1016/0924-4212(96)84889-4. 

19. Huber P.E., Debus J., Latz D., et al. Radiotherapy for Advanced Adenoid Cystic Carcinoma: Neutrons, Photons or Mixed Beam? Radiother Oncol. 2001;59:161-167. https://doi.org/10.1016/s0167-8140(00)00273-5 10.1016/s0167-8140(00)00273-5.

20. Davis C., Sikes J., Namaranian P., Laramore G., Dillon J.K. Neutron Beam Radiation Therapy: an Overview of Treatment and Oral Complications when Treating Salivary Gland Malignancies. J. Oral. Maxillofac Surg. 2016;74:830-835. https://doi.org/10.1016/j.joms.2015.10.014 10.1016/j.joms.2015.10.014.

 PDF (RUS) Full-text article (in Russian)

Conflict of interest. The authors declare no conflict of interest.

Financing. The study had no sponsorship.

Contribution. Article was prepared with equal participation of the authors.

Article received: 20.07.2023. Accepted for publication: 27.08.2023.